The first in vivo study in the GOT1 animal model showed that curative amounts of 177Lu-octreotate resulted in lower expression of SSTRs during the time period studied: 4 h to 13 days (reflected by lower tumor uptake of subsequently injected 111In-octreotide) [28]. Here, GOT1 is linked to neoplasm.